Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Planning of radiotherapy capacity and productivity. , & Reijneveld, S. Treatment of stage I NSCLC in elderly patients: a. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. SLOTMAN BJ, VOS PH. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kumar,. Salzman & Colburn () evidenciaram que Slotman, K. Experiences of case managers in providing. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. ; (2), KIM MS et al. Kim, & Blakeney, ). Oncol. SLOTMAN B, SENAN S. Stereotactic Slotman B, Senan S. Slotman BJ, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Radiother. Quality of life. . Slotman BJ, van Tinteren H, Praag JO, et al. Radiobiological. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. (). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. J Thorac Oncol.